| 结直肠癌化疗进展 |
| |
| 引用本文： | 蒋蔚茹,刘杰.结直肠癌化疗进展[J].中国肿瘤,2011,20(3):200-203. |
| |
| 作者姓名： | 蒋蔚茹 刘杰 |
| |
| 作者单位： | 复旦大学消化病研究所,复旦大学附属华山医院,上海,200040 |
| |
| 摘 要： | 在过去的20年中,无论是针对术后结直肠癌的辅助化疗或是转移性结直肠癌的化疗均取得了令人鼓舞的进展。在20世纪80年代末,仅有5-Fu一种化疗药物可选用,现在已经有了奥沙利铂、伊立替康、卡培他滨、贝伐单抗、西妥昔单抗等多种药物组成联合化疗方案供选择。通过目前的化疗方案治疗,75%的结直肠癌患者术后3年无复发,50%晚期结直肠癌患者生存期达2年。文章重点对化疗在辅助治疗与转移结直肠癌治疗中的作用进行了综述。
|
| 关 键 词： | 结直肠癌 化疗 辅助治疗 转移性结直肠癌 |
Progression in Chemotherapy for Colorectal Cancer |
| |
| JIANG Wei-ru,LIU Jie.Progression in Chemotherapy for Colorectal Cancer[J].Bulletin of Chinese Cancer,2011,20(3):200-203. |
| |
| Authors: | JIANG Wei-ru LIU Jie |
| |
| Institution: | JIANG Wei-ru,LIU Jie(Institute of Digestive Diseases,Fudan University,Huashan Hospital of Fudan University,Shanghai 200040,China) |
| |
| Abstract: | The progress in the past 2 decades in the chemotherapy for colorectal cancer(CRC) whether in the adjuvant setting or in the advanced setting is encouraging.In the late 1980s,only 5-Fluorouracil(5-Fu) was available in the treatment of CRC.Now,oxaliplatin,capecitabine,irinotecan,bevacizumab,cetuximab have been incorporated into several regimens.With present therapy,75% of patients with localized disease are recurrence free at 3 years after operation,and up to 50% of patients with advanced unresectable disease... |
| |
| Keywords: | colorectal cancer chemotherapy adjuvant therapy metastatic colorectal cancer |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
